版本:
中国

BRIEF-FDA clears Flex Pharma's FLX-787 to commence US phase 2 trial in ALS under IND

April 26 Flex Pharma Inc:

* FDA clears Flex Pharma's FLX-787 to commence us phase 2 trial in ALS under ind

* FDA clears flex Pharma's FLX-787 to commence us phase 2 trial in ALS under IND

* Flex Pharma Inc - expects to begin enrolling us patients this summer in this randomized, controlled, double-blinded, parallel design study

* Flex Pharma Inc - in addition, company has exploratory phase 2 studies currently ongoing in patients with ms and ALS in Australia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐